Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab in Treatment-Naive CLL (Phase 3)
CTR20241195Phase 3Active
- Sponsor
- BeiGene
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sonrotoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by BeiGene. Started May 2024; status: active.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20241195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241195.